Xerox and Vortran Medical Partnering Allows for Mass Produce of Disposable Ventilators

Xerox Holdings Corporation and Vortran Medical Technology are teaming up to speed and scale production of Vortran’s GO2Vent ventilator and related Airway Pressure Monitor (APM-Plus) for hospitals and emergency response units fighting the battle against COVID-19.

The two companies expect to work together to quickly respond to the shortage of critical ventilation equipment necessary to support patients breathing. Assuming a stable supply of essential parts, the companies will be rapidly scaling up production from approximately 40,000 ventilators in April to between 150,000 and 200,000 ventilators a month by June. Together, Xerox and Vortran could produce as many as 1 million ventilators in the coming months.

While the GO2Vent is not a replacement for ventilators found in intensive care units (ICUs), it is widely used in emergency situations, inter-hospital transport and MRIs. Given the shortage of ICU-grade ventilators, medical professionals are utilizing tools like this and other technology to support patients who do not yet or no longer need an ICU-level breathing device, which can be freed up for another patient.

“Our smartest minds met (virtually) with Vortran’s smartest minds and figured out how to mass-produce this critical technology,” said John Visentin, vice chairman and chief executive officer, Xerox. “We want to help make sure doctors, nurses and paramedics on the frontlines have the resources they need to help the rising number of patients with COVID-19.”

Xerox plans to manufacture these FDA-approved ventilators and APM-Plus devices at its facility outside of Rochester, NY, where the company was founded and maintains a large presence. Vortran will continue to manufacture ventilators at its current facility in Sacramento, CA.

“The partnership with Xerox has one clear goal – to help save as many lives as possible. With Vortran’s proven technology and Xerox’s ability to hyper-scale manufacturing, we believe we can supply healthcare providers as many as 1 million ventilators in the coming months,” said Vortran Co-founder and CEO, Gordon A. Wong, M.D. “For all of us, this will be the most important thing we ever do.”

Vortran’s GO2Vent was designed for emergency use, natural disasters and disease outbreaks such as the COVID-19 pandemic. A gas-operated, disposable ventilator that can be set-up within minutes and discarded after use by a single patient, it provides support via a secure airway and can be operated on a compressor, oxygen or air with a minimum of 10 liters per minute flow rates.

The GO2Vent can provide continuous ventilatory support for up to 30 days and operates independently of Vortran’s APM-Plus. The APM-Plus is a battery-operated, portable device that connects to a GO2Vent and provides enhanced monitoring of patient status and key respiratory parameters. Given the need to confirm key supplies, the companies are actively assessing how quickly production can ramp for the APM-Plus devices.

In addition to scaling up production of the GO2Vent and APM-Plus, Xerox and Vortran expect to compile and analyze data and feedback from healthcare professionals on the frontlines of the battle against COVID-19 in order to design and mass-produce external, in-line modifications that can be added to the GO2Vent to expand the potential applications of this life-saving equipment.

Both Xerox and Vortran will distribute the products.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”